Tevogen Bio (NASDAQ:TVGN) Receives "Sell (E+)" Rating from Weiss Ratings

Key Points

• Tevogen Bio's stock has been given a "Sell (E+)" rating by Weiss Ratings, while D. Boral Capital maintains a "Buy" rating with a price target of $10.00.
• The stock recently traded at $0.67, marking a 4.8% increase, although it remains well below its 52-week high of $3.09.
• Nuveen LLC acquired a new stake in Tevogen Bio, purchasing 90,253 shares valued at approximately $97,000.

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "sell (e+)" rating reiterated by stock analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Separately, D. Boral Capital reiterated a "buy" rating and set a $10.00 price objective on shares of Tevogen Bio in a research report on Thursday, September 4th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Tevogen Bio currently has an average rating of "Hold" and an average price target of $10.00.

Tevogen Bio Stock Up 4.8%

Shares of NASDAQ:TVGN traded up $0.03 during midday trading on Friday, hitting $0.67. The stock had a trading volume of 223,115 shares, compared to its average volume of 510,887. The company's 50-day moving average price is $0.81 and its 200-day moving average price is $1.02. The company has a market capitalization of $131.07 million, a P/E ratio of -3.51 and a beta of -0.83. Tevogen Bio has a fifty-two week low of $0.61 and a fifty-two week high of $3.09.

Tevogen Bio (NASDAQ:TVGN - Get Free Report) last issued its earnings results on Tuesday, August 19th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.02.

Hedge Funds Weigh In On Tevogen Bio

A hedge fund recently bought a new stake in Tevogen Bio stock. Nuveen LLC bought a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 90,253 shares of the company's stock, valued at approximately $97,000.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.